BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

CIT Opens New U.S. Subsidiary, CITox, Inc.


9/27/2010 11:54:26 AM

Evreux, France, September 27, 2010 – CIT, a leading European non-clinical CRO announced today the opening of its new U.S. subsidiary, CITox, Inc. The new company is based in Boston, Massachusetts, and will spearhead CIT’s planned expansion of its U.S. activities.

CIT simultaneously announced the appointment of Bernard Galat, 55, as Vice-President Business Development, North America. Galat is a U.S. citizen and will be based in the Boston office.

“We are excited to make this significant investment which affirms CIT’s commitment to our North American clients and provides the opportunity to deliver an even higher quality of service as we increase our market share,” said Sophie Baratte, CIT CEO.

The U.S. represents 15 per cent of CIT’s current sales today, and the company aims to increase this to 30 per cent in three to five years.

“CIT is also pleased to introduce Bernard Galat and announce this key appointment as a further indication of our continued customer centric growth,” said Baratte. “Bernard has a strong background in serving customer needs and developing high value relationships. The additional benefits derived from his knowledge and experience in driving market expansion and revenues will be integral to the growth of CIT.”

Prior to joining CIT, Galat held senior sales and marketing positions with Xceleron Inc., Parexel International and Carestat, Inc. Formerly, he served as Vice President of Sales, Marketing and Clinical Applications for Ultracision, Inc. There, he recruited, trained and managed a global sales force and led cross-functional teams to establish priorities for new product development. Johnson & Johnson acquired Ultracision for a multiple equal to ten times sales.

Galat received a BS magna cum laude from Northeastern University in Biology and Communications and earned an MBA with honors from Northeastern’s Graduate School of Business.

“This is an exciting time to be joining CIT as we expand the availability of our services in monoclonal antibody therapies, tissue cross-reactivity, functional genomics, safety pharmacology and carcinogenicity, including transgenic models” said Galat. “These sophisticated technologies will continue to develop and play an evermore important role in drug development.”

Details of the Boston office:

CIT 82 Broad Street Suite 315 Boston, MA, 02110

Tel: 603-601-6389

About CIT http://www.citox.com

CIT is a science-driven, independent, non-clinical contract research organization (CRO) specialized in safety and health research. Founded in 1969, CIT has carried out a vast number of projects for international companies on human and veterinary pharmaceuticals, biotechnology, chemicals, agrochemicals and consumer products. It has contributed to many product registrations around the world.

With a staff of 360, CIT offers a full range of research in general toxicology, reproductive toxicology, carcinogenicity, pharmacokinetics and safety pharmacology. The company also carries out research into genetic toxicology, in vitro testing and toxicogenomics.

Its 20,000 sq m (215,000 sq ft) facilities located in Normandy, one hour from Paris, France, house all principal laboratory animal species to the highest standards. Laboratory facilities include analytical chemistry and bioanalysis, clinical pathology, genomics and histology. Support facilities include archives and plant buildings. The company is GLP and AAALAC certified.

More than half the company’s business comes from international customers. Overall, 80 per cent of revenues are in the pharmaceutical and biotechnology sector. Biotechnology and start-up companies alone account for 50 per cent.

The company has a world-class team of top-level management in scientific, financial and business activities.

Lynne Chapman ANDREW LLOYD & ASSOCIATES http://www.ala.com lynne@ala.com

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND Tel: +44 1273 675100 Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION


Read at BioSpace.com


CIT
CITox, Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->